CAR Stock Recent News

Reactivation of P-BCMA-101 CAR-T cells and a repeat stringent complete response (sCR) more than 3 years after original CAR-T therapy Demonstrates potential of stem cell memory T cells (TSCM), a key differentiator for Poseida's CAR-T programs  SAN DIEGO , Sept. 4, 2024 /PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage allogeneic cell therapy and genetic medicines company advancing differentiated non-viral treatments for patients with cancer and rare diseases, highlighted new data from a case study of a patient with relapsed multiple myeloma treated in a clinical trial of P-BCMA-101, the Company's original investigational T stem cell memory (TSCM)-rich BCMA targeting autologous CAR-T cell therapy.

SAN JOSE, Calif. , Sept. 3, 2024 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that the inventor of its ovarian cancer CAR-T technology, Jose R.

Galapagos NV achieved positive results from its European phase 1/2 ATLANTA-1 study using GLPG5101 for patients with relapsed/refractory NHL; phase 1 portion with 87.5% ORR and phase 2 portion with 93.3% ORR. The global non-Hodgkin Lymphoma market is expected to reach $16 billion by 2029; on average, between 30% to 40% of NHL patients have relapsed/refractory disease. IND clearance of U.S. phase 1/2 ATLANTA-1 study using GLPG5101 for patients with relapsed/refractory NHL achieved; this trial could speed up enrollment and further establish efficacy with newly added patients.

Marker Therapeutics to receive non-dilutive funding from NIH Small Business Innovation Research Program based on preliminary clinical results and non-clinical data in lymphoma Marker Therapeutics to receive non-dilutive funding from NIH Small Business Innovation Research Program based on preliminary clinical results and non-clinical data in lymphoma

Canadian Apartment Properties Real Estate Investment Trust (OTC:CDPYF) Q2 2024 Earnings Conference Call August 8, 2024 9:00 AM ET Company Participants Nicole Dolan - Investor Relations Mark Kenney - President and Chief Executive Officer Julian Schonfeldt - Chief Investment Officer Stephen Co - Chief Financial Officer Conference Call Participants Fred Blondeau - Green Street Jonathan Kelcher - TD Cowen Mario Saric - Scotiabank Kyle Stanley - Jarden Jimmy Shan - RBC Matt Kornack - National Bank Sairam Srinivas - Cormark Securities Dean Wilkerson - CIBC Operator Good morning. Thank you for attending today's Canadian Apartment Properties Second Quarter 2024 Results Conference Call.

Avis Budget Group's (CAR) second-quarter 2024 earnings and revenues decrease on a year-over-year basis.

Avis Budget Group, Inc. (NASDAQ:CAR ) Q2 2024 Earnings Conference Call August 6, 2024 8:30 AM ET Company Participants David Calabria - Senior Vice President, Corporate Finance and Treasurer Joseph Ferraro - President and Chief Executive Officer Izzy Martins - Executive Vice President and Chief Financial Officer Conference Call Participants Chris Woronka - Deutsche Bank Ryan Brinkman - JPMorgan John Babcock - Bank of America Lizzie Dove - Goldman Sachs Stephanie Moore - Jefferies Operator Greetings. Welcome to the Avis Budget Group Second Quarter 2024 Earnings Conference Call.

The headline numbers for Avis Budget (CAR) give insight into how the company performed in the quarter ended June 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Avis Budget Group (CAR) came out with quarterly earnings of $0.41 per share, missing the Zacks Consensus Estimate of $2.60 per share. This compares to earnings of $11.01 per share a year ago.

PARSIPPANY, N.J., Aug. 05, 2024 (GLOBE NEWSWIRE) -- Avis Budget Group, Inc. (NASDAQ: CAR) announced financial results for second quarter 2024 today.